Reinforcement of the intestinal mucosal barrier via mucus-penetrating PEGylated bacteria

IF 26.8 1区医学 Q1 ENGINEERING, BIOMEDICAL

Nature Biomedical Engineering Pub Date : 2024-06-05 DOI:10.1038/s41551-024-01224-4

Yanmei Chen, Sisi Lin, Lu Wang, Yifan Zhang, Huan Chen, Zhenzhen Fu, Mengmeng Zhang, Huilong Luo, Jinyao Liu

{"title":"Reinforcement of the intestinal mucosal barrier via mucus-penetrating PEGylated bacteria","authors":"Yanmei Chen, Sisi Lin, Lu Wang, Yifan Zhang, Huan Chen, Zhenzhen Fu, Mengmeng Zhang, Huilong Luo, Jinyao Liu","doi":"10.1038/s41551-024-01224-4","DOIUrl":null,"url":null,"abstract":"The breakdown of the gut’s mucosal barrier that prevents the infiltration of microorganisms, inflammatory cytokines and toxins into bodily tissues can lead to inflammatory bowel disease and to metabolic and autoimmune diseases. Here we show that the intestinal mucosal barrier can be reinforced via the oral administration of commensal bacteria coated with poly(ethylene glycol) (PEG) to facilitate their penetration into mucus. In mice with intestinal homoeostatic imbalance, mucus-penetrating PEGylated bacteria preferentially localized in mucus at the lower gastrointestinal tract, inhibited the invasion of pathogenic bacteria, maintained homoeostasis of the gut microbiota, stimulated the secretion of mucus and the expression of tight junctions, and prevented the mice from developing colitis and diabetes. Orally delivered PEGylated bacteria may help prevent and treat gastrointestinal disorders. The intestinal mucosal barrier can be reinforced via the oral administration of commensal bacteria coated with poly(ethylene glycol) to facilitate their penetration into mucus.","PeriodicalId":19063,"journal":{"name":"Nature Biomedical Engineering","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Biomedical Engineering","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41551-024-01224-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The breakdown of the gut’s mucosal barrier that prevents the infiltration of microorganisms, inflammatory cytokines and toxins into bodily tissues can lead to inflammatory bowel disease and to metabolic and autoimmune diseases. Here we show that the intestinal mucosal barrier can be reinforced via the oral administration of commensal bacteria coated with poly(ethylene glycol) (PEG) to facilitate their penetration into mucus. In mice with intestinal homoeostatic imbalance, mucus-penetrating PEGylated bacteria preferentially localized in mucus at the lower gastrointestinal tract, inhibited the invasion of pathogenic bacteria, maintained homoeostasis of the gut microbiota, stimulated the secretion of mucus and the expression of tight junctions, and prevented the mice from developing colitis and diabetes. Orally delivered PEGylated bacteria may help prevent and treat gastrointestinal disorders. The intestinal mucosal barrier can be reinforced via the oral administration of commensal bacteria coated with poly(ethylene glycol) to facilitate their penetration into mucus.

Abstract Image

查看原文本刊更多论文

通过粘液穿透性聚乙二醇化细菌强化肠粘膜屏障

肠道粘膜屏障可防止微生物、炎症细胞因子和毒素渗入身体组织，如果屏障遭到破坏，就会导致炎症性肠病以及代谢性和自身免疫性疾病。在这里，我们展示了可以通过口服涂有聚（乙二醇）（PEG）的共生细菌来加强肠道粘膜屏障，从而促进其渗透到粘液中。在肠道平衡失调的小鼠中，粘液渗透性 PEG 化细菌优先定位于胃肠道下部的粘液中，抑制了致病菌的入侵，维持了肠道微生物群的平衡，刺激了粘液的分泌和紧密连接的表达，防止了小鼠患结肠炎和糖尿病。口服 PEG 化细菌可能有助于预防和治疗胃肠道疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Biomedical Engineering Medicine-Medicine (miscellaneous)

CiteScore

45.30

自引率

1.10%

发文量

138

期刊介绍： Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.